Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects three bowel cancer drugs

The National Institute for Health and Clinical Excellence (NICE) has decided to not recommend three metastatic colorectal cancer drugs as they are not deemed cost effective

The National Institute for Health and Clinical Excellence (NICE) has rejected three drugs for the treatment of metastatic colorectal cancer, as they do not represent value for money.

NICE decided not to recommend Roche's Avastin, Merck KGaA's Erbitux and Amgen's Vectibix, as the high cost of the drugs could not be justified. The agency said that no convincing data was presented to demonstrate the extension of life for a patient with the disease.

NICE has currently recommended six treatments for the various stages of colorectal cancer, and commented that it was “disappointed not to be able to recommend” the three drugs.

Around 20-55 per cent of people with colorectal cancer have metastatic disease by the time of diagnosis.

The companies have been allowed to submit further comments on the committee's interpretation of their products, or consider reducing their prices.

5th September 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics